B+
Bull case
25%
Probability
Target price
$70.00
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
TGTX
TG TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$55.00
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$42.00
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-06
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+67.3
Score
AI commentary
The company-source tone is constructive after strong Q2 revenue, raised guidance, positive ENHANCE results, and dated development milestones. However, later post-earnings market reaction and analyst revisions remain thin: the available analyst evidence is pre-print, and no reliable post-print price attribution was verified. Direct MS comparators improve the peer context, but the thesis remains a cautious monitoring view rather than a high-conviction upgrade.
RankAlpha Sentiment Codex - 2026-08-06
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-08-03eventQ2 commercial strength and raised BRIUMVI guidanceMedium impact
Q2 2026 total global revenue was approximately $240.3 million, including $227.7 million of BRIUMVI U.S. net product revenue, up approximately 64% year over year. TG Therapeutics raised its full-year 2026 global revenue target to approximately $950 million and BRIUMVI U.S. revenue target to approximately $890-$905 million. [#SEC-8K-2026-08-03]
2026-11-04catalystPost-print expectation digestionMedium impact
The deterministic post-earnings prior turned negative despite strong reported results, indicating elevated expectations and possible near-term profit-taking. No reliable post-print price attribution or analyst revision tape was verified, so this remains a risk rather than confirmed market reaction.
2027-08-06catalystSubcutaneous BRIUMVI Phase 3 readoutHigh impact
Phase 1 data supported a quarterly subcutaneous dosing regimen, and the fully enrolled Phase 3 trial is expected to produce top-line data at year-end 2026 or in the first quarter of 2027. Success could improve administration convenience and adoption, but regulatory and commercial outcomes remain uncertain. [#SEC-8K-2026-08-03]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-06 • Updated nightlySource: Internal modelMethodology